New drug AVP-786 passes first safety check in healthy people
NCT ID NCT02174835
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tested a new drug, AVP-786, in 56 healthy adult men to see how the body processes it and whether it is safe. The drug is a modified version of dextromethorphan combined with quinidine. Because this is a Phase 1 study in healthy people, it does not test whether the drug works for any disease, but it is a necessary first step before testing in patients.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- AVP-786 (deuterated dextromethorphan/quinidine)
- What this could lead to
- If successful, this early study could support further testing of AVP-786 for conditions like agitation in Alzheimer's disease.
- What could go wrong
- This is a very early Phase 1 trial in only 56 healthy volunteers, so it cannot prove the drug works for any disease. Side effects or lack of benefit may emerge in later studies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CMAX
Adelaide, South Australia, 5000, Australia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a new oral drug change future treatments? early safety trial begins
- Can brain scans unlock the secret to hearing in crowded rooms?
- Can a Light-Guided device make arterial sticks easier?
- Water workouts could be the key to back pain relief
- Could everyday disinfectants be harming us? a new study investigates
- Can a new drug keep the Heart's beat steady? trial puts verducatib to the test